AbCellera Biologics

AbCellera Biologics, Inc. engages in the development of therapeutic antibodies. It offers antibody discovery platform that searches, decodes and analyzes natural immune systems to find antibodies that can be developed to prevent and treat disease. The company was founded by Carl Lars G. Hensen, Kathleen Lisaingo, Kevin Heyries, Véronique Lecault and Daniel Da Costa on November 8, 2012 and is headquartered in Vancouver, Canada.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

AbCellera Biologics reports robust earnings and growth opportunities ahead

AbCellera Biologics demonstrated strong financials and growth in Q4 2022, with a focus on building an engine for antibody discovery and development.
The company's strategic approach to partnerships and contract negotiations provides flexibility and potential for increased value creation.
Despite challenges in decision-making and program advancement, AbCellera's business model and liquidity position position it well for future opportunities.

AbCellera Biologics (ABCL) reports solid Q1 performance and eyes strategic growth opportunities

AbCellera Biologics (ABCL) showcases a strong performance in Q1 2023, focusing on long-term value creation and strategic partnerships.
Despite challenges in revenue streams and resource allocation, the company's emphasis on technology development and program diversity bodes well for future growth.
Opportunities lie in expanding partnerships, leveraging advancements in cancer therapy, and driving innovation in drug development for sustained success.

AbCellera reports Q2 revenue growth, faces clinical development uncertainty

AbCellera Biologics reported mixed financial results for Q2 2023, with revenue growth but a net loss due to continued investments.
The company showcased strengths in patent defense, R&D capabilities, and partnerships, while facing challenges in clinical development uncertainty and financial performance.
Opportunities lie in global therapeutics discovery, liquidity strength, and collaboration with Eli Lilly for COVID-19 antibody development, positioning AbCellera for future growth.

AbCellera reports Q3 results, advances innovative therapies and partnerships

AbCellera Biologics reported mixed financial results in Q3 2023 but demonstrated commitment to advancing innovative therapies and strategic partnerships.
Strengths lie in promising assets, financial stability, innovative molecule design, and progress on development candidates, while challenges include profitability concerns and operational complexities.
Opportunities for growth include expanding the product pipeline, exploring novel treatments through partnerships, and optimizing therapies for improved patient outcomes and market positioning.
Overall, AbCellera's performance reflects a balance of financial stability, innovation, and strategic focus, with future updates poised to drive investor interest and market impact.

AbCellera Biologics reports Q1 performance, highlights partnerships and growth

AbCellera Biologics showcased strong performance in Q1 2024, with a focus on advancing internal programs, strategic partnerships, and technological innovations.
Despite financial challenges, the company's strengths lie in its robust pipeline, strong financial position, and promising partnerships with industry leaders.
Navigating challenges in profitability and market competition, AbCellera has significant opportunities to drive growth through partnerships, technological advancements, and market expansion.

AbCellera Biologics reports Q2 revenue growth and strategic partnerships

AbCellera Biologics' Q2 2024 performance reflects a strong financial position, progress in key programs, and strategic partnerships driving future growth.
While facing challenges in profitability and research fee reductions, the company's focus on innovation and partnerships presents opportunities for market expansion.
Overall, AbCellera's emphasis on internal pipeline development and strategic collaborations positions them well for long-term success in the biologics industry.

AbCellera Biologics reports Q3 loss but poised for clinical advancements

AbCellera Biologics is navigating its transition to a clinical stage biotech with promising programs and a strong financial position.
While facing challenges in managing R&D expenses and achieving profitability, the company's strategic moves and preparedness for clinical trials bode well for future growth.
Opportunities lie in further investments in development, advancing novel therapies, and leveraging its financial strength to capitalize on emerging opportunities.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

VANCOUVER, British Columbia--(BUSINESS WIRE)---- $ABCL--AbCellera Presents New Data on T-Cell Engager Platform at AACR 2023

AbCellera Presents New Data on T-Cell Engager Platform at AACR 2023

Alphabet

Intuitive Surgical

Alphabet has multiple ways to profit from greater use of AI in the healthcare sector. Intuitive Surgical is working on using AI to improve robotic surgery.

1 Sector Received $6.1 Billion in AI Investments Last Year: 3 Top Stocks to Buy

AdTheorent Holding Company Inc

B2Gold

Hudson Technologies

Navitas Semiconductor Corp

Radiant Logistics

TDCX

Although financial advisors often direct you to established, reliable enterprises, in some cases, you can find compelling ideas among the best stocks under $10. To be fair, such companies tend to be more volatile than your standard blue-chip fare.

7 Best Stocks Under $10 to Buy in April

VANCOUVER, British Columbia--(BUSINESS WIRE)---- $ABCL--AbCellera to Present at the 2023 Bloom Burton & Co.

AbCellera to Present at the 2023 Bloom Burton & Co. Healthcare Investor Conference on April 25, 2023

VANCOUVER, British Columbia--(BUSINESS WIRE)---- $ABCL--AbCellera to Report First Quarter 2023 Financial Results on May 4, 2023

AbCellera to Report First Quarter 2023 Financial Results on May 4, 2023

Chimerix

Kiniksa Pharmaceuticals Ltd

Ocuphire Pharma

Point Biopharma Global

Vaccitech

Vir Biotechnology

While it might be difficult to navigate the equities sector now amid various headwinds, biotech stocks to buy may offer a surprising respite. True, the market presence of the surprise production cuts by the Organization of the Petroleum Exporting Countries (OPEC) and non-member oil-producing nations — known as OPEC+ — along with the Federal Reserve's possible response.

7 Thrilling Biotech Stocks for Aggressive Investors to Buy

Analog Devices

Amazon

Alexandria Real Estate Equities

Anheuser-Busch InBev

Coda Octopus Group

Canadian Pacific Kansas City Limited

Charles River Laboratories

Salesforce

CrowdStrike

Dominion Energy

Datadog

Diageo

Disney

Dynatrace Inc

Duke Energy

Essex Property Trust

Coppersteel Holdco Inc

General Mills

Corning

Hannon Armstrong Sustainable Infrastructure Capital

Honeywell

Intel

Most readers follow my work for the extensive writing I have done referencing my aggressive growth portfolio. However, the vast majority of my net worth is held in my all-weather portfolio. In this article, I would like to draw back the curtain on my main, all-weather portfolio, where roughly 80% of my assets reside.

Confounded's Complete All-Weather Portfolio Revealed

Evolution Petroleum

VAALCO Energy

Sensus Healthcare

If you aspire to one day topple entrepreneurial genius Elon Musk on the net wealth rankings through the equities market exclusively, you're obviously going to need to conduct heavy research on the stocks that can make you rich. However, you also want to be smart about this.

7 Stocks to Bet On if You Want to Be Richer Than Elon Musk

VANCOUVER, British Columbia & LONDON--(BUSINESS WIRE)---- $ABCL--AbCellera and RQ Bio Partner to Accelerate the Advancement of New Therapies for Infectious Disease

AbCellera and RQ Bio Partner to Accelerate the Advancement of New Therapies for Infectious Disease

VANCOUVER, British Columbia--(BUSINESS WIRE)---- $ABCL--AbCellera Announces Two Presentations on T-Cell Engager Discovery at AACR 2023

AbCellera Announces Two Presentations on T-Cell Engager Discovery at AACR 2023

VANCOUVER, British Columbia--(BUSINESS WIRE)---- $ABCL--AbCellera to Present at the Cowen 43rd Annual Health Care Conference on March 6, 2023

AbCellera to Present at the Cowen 43rd Annual Health Care Conference on March 6, 2023

AbCellera Biologics Inc. (ABCL) delivered earnings and revenue surprises of -1,100% and 62.63%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

AbCellera Biologics Inc. (ABCL) Reports Q4 Loss, Misses Revenue Estimates

AbCellera Biologics Inc. (NASDAQ:ABCL ) Q4 2022 Earnings Conference Call February 21, 2023 5:00 PM ET Company Participants Tryn Stimart - Chief Legal and Compliance Officer Carl Hansen - Chairman, Chief Executive Officer, and President Andrew Booth - Chief Financial Officer Conference Call Participants Tiago Fauth - Credit Suisse Andrea Tan - Goldman Sachs Gary Nachman - BMO Robyn Karnauskas - Truist Gaurav Goparaju - Berenberg Antonia Borovina - Bloom Burton Operator Good afternoon. And welcome to AbCellera's Full-Year 2022 Business Update Conference Call.

AbCellera Biologics Inc (ABCL) Q4 2022 Earnings Call Transcript

VANCOUVER, British Columbia--(BUSINESS WIRE)---- $ABCL--AbCellera Reports Full Year 2022 Business Results

AbCellera Reports Full Year 2022 Business Results

BioNTech SE

iTeos Therapeutics, Inc.

Moderna

Regeneron Pharmaceuticals

You don't have to be particularly astute to recognize the importance of the most undervalued biotech stocks to buy. Fundamentally, the enterprises that undergird these names operate on the cutting edge of medical science.

The 7 Most Undervalued Biotech Stocks to Buy in February 2023

VANCOUVER, British Columbia--( BUSINESS WIRE )--AbCellera (Nasdaq: ABCL) today announced that it will present at the SVB Securities Global Biopharma Conference on Wednesday, February 15, 2023, at 10:00 a.m. Pacific Time (1:00 p.m. Eastern Time).

AbCellera to Present at the SVB Securities Global Biopharma Conference on February 15, 2023

VANCOUVER, British Columbia--( BUSINESS WIRE )--AbCellera (Nasdaq: ABCL) will announce its full year 2022 financial results on Tuesday, February 21, 2023, and hold an earnings conference call at 2:00 p.m. Pacific Time (5:00 p.m. Eastern Time) the same day.

AbCellera to Report Full Year 2022 Financial Results on February 21, 2023

Investors need to pay close attention to AbCellera (ABCL) stock based on the movements in the options market lately.

Is the Options Market Predicting a Spike in AbCellera (ABCL) Stock?

VANCOUVER, British Columbia--( BUSINESS WIRE )--AbCellera (Nasdaq: ABCL) today announced that the United States Patent and Trademark Office's Patent Trial and Appeal Board (PTAB) has ruled in favor of AbCellera in an Inter Partes Review (IPR) filed by Berkeley Lights, Inc. (Berkeley Lights) that challenged AbCellera's U.S. Patent No. 10,087,408 (the ‘408 Patent). AbCellera's ‘408 Patent is directed to microfluidic devices and using such devices to culture cells, monitor a response, and recover selected cells.

AbCellera Announces that the U.S. Patent Trial and Appeal Board Upholds Microfluidic Cell Culture Patent

In this article, I will provide my valuation model for AbCellera, building on an article I wrote over a year ago. In the last year, many of my inputs I previously used have changed, given the greater transparency of the company throughout 2022. Some for the better, some for the worse.

AbCellera Biologics: My Updated Current Valuation Estimate

VANCOUVER, British Columbia--( BUSINESS WIRE )--AbCellera (Nasdaq: ABCL) today announced that executives from the Company will present at the 41st Annual J.P. Morgan Healthcare Conference on Wednesday, January 11, 2023, at 2:15 p.m. Pacific Time (5:15 p.m. Eastern Time).

AbCellera to Present at the 41st Annual J.P. Morgan Healthcare Conference on January 11, 2023

AST SpaceMobile

Beam Therapeutics

CRISPR Therapeutics

Editas Medicine

JFrog

HashiCorp

Maxar Technologies

MongoDB

Intellia Therapeutics

UiPath

Planet Labs

Prime Medicine Inc

Rocket Lab USA

Sumo Logic

Tesla

While others flock to safety, should you do the opposite? Some of the best times to invest in highly speculative names are when no one wants them, as long as the reasons are macro and not company or industry specific.

10 Potential 10x Return Stocks For The Next 10 Years

AbCellera (ABCL) inks a strategic collaboration with AbbVie to develop new antibody therapies across multiple indications. ABCL shares rise.

AbCellera (ABCL) to Develop New Antibody Therapies With AbbVie

VANCOUVER, British Columbia--( BUSINESS WIRE )--AbCellera (Nasdaq: ABCL) announced today that it has entered into a multi-year, multi-target strategic collaboration with AbbVie Inc. (NYSE: ABBV). The partnership will leverage AbCellera's antibody discovery and development engine to deliver optimized development candidates for up to five targets selected by AbbVie across multiple indications.

AbCellera and AbbVie Partner to Advance New Antibody Therapies

Rallybio Corp

VANCOUVER, British Columbia & NEW HAVEN, Conn.--( BUSINESS WIRE )--AbCellera (Nasdaq: ABCL) and Rallybio Corporation (Nasdaq: RLYB) announced today that they have entered into a strategic alliance to discover, develop, and commercialize novel antibody-based therapeutics for rare diseases. This multi-year, multi-target collaboration will combine AbCellera's antibody discovery engine with Rallybio's clinical and commercial expertise in rare diseases to identify optimal clinical candidates and ultimately deliver therapies to patients.

AbCellera and Rallybio Announce Strategic Alliance to Discover, Develop, and Commercialize Novel Antibody-Based Therapeutics for Rare Diseases

News for AbCellera Biologics Stock (ABCL)